Syncona supplied a third of the investment and retains a majority stake in Freeline, which is based on research at UCL.

Freeline, a UK-based gene therapy spinout from University College London (UCL) formed by commercialisation firm Syncona, today closed a $120m series C round featuring the latter investor. Pharmaceutical firm Novo Holdings, investment adviser Eventide Asset Management and investment management firm Wellington Management Company co-led the round, which also featured Cowen Healthcare Investments, Acorn Bioventures and…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.